Entasis Therapeutics Holdings Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETTX research report →
Companywww.entasistx.com
Entasis Therapeutics Holdings Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.
- CEO
- Manoussos Perros
- IPO
- 2018
- Employees
- 51
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -2.20
- P/S
- 0.00
- P/B
- 3.32
- EV/EBITDA
- 0.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -112.91%
- ROIC
- -151.03%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-47,141,000 · 6.64%
- EPS
- $-1.00 · 52.38%
- Op Income
- $-47,141,000
- FCF YoY
- 5.29%
Performance & Tape
- Beta
- 1.33
Get TickerSpark's AI analysis on ETTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 8, 22 | Innoviva Strategic Opportunities LLC | buy | 7,598,814 |
| Jul 11, 22 | Tommasi Ruben | other | 24,858 |
| Jul 11, 22 | Tommasi Ruben | other | 6,465 |
| Jul 11, 22 | Tommasi Ruben | other | 50,000 |
| Jul 7, 22 | Tommasi Ruben | other | 39,596 |
| Jul 11, 22 | Tommasi Ruben | sell | 150,000 |
| Jul 11, 22 | Tommasi Ruben | other | 98,700 |
| Jul 11, 22 | Perros Manoussos | other | 69,970 |
| Jul 7, 22 | Perros Manoussos | other | 56,072 |
| Jul 11, 22 | Perros Manoussos | other | 325,755 |
Our ETTX Coverage
We haven't published any research on ETTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ETTX Report →